In a change of plans, Nektar spins out its opioid into a new biotech subsidiary as FDA PDUFA date looms
Nektar Therapeutics is spinning off a new biotech company and gifting it with their late-stage pain drug NKTR-181 just three months ahead of a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
